Aurinia Pharmaceuticals Inc. — Q2 2023 Form 10-Q
Reporting period: Three and six months ended June 30, 2023. Figures are in U.S. dollars; financial statement amounts below are in millions unless stated otherwise. Aurinia is a commercial-stage biopharmaceutical company whose principal product is LUPKYNIS (voclosporin), approved in the U.S. for adults with active lupus nephritis. The company also has preclinical programs AUR200 and AUR300.
Financial performance
| Metric | Q2 2023 | Q2 2022 | H1 2023 | H1 2022 |
|---|---|---|---|---|
| Total revenue | $41.5 | $28.2 | $75.9 | $49.8 |
| Net product revenue | $41.1 | $28.1 | $75.4 | $49.6 |
| Gross margin | 96% | 94% | 97% | 96% |
| Operating loss | $(16.2) | $(36.0) | $(45.8) | $(73.9) |
| Net loss | $(11.5) | $(35.5) | $(37.7) | $(73.1) |
| Loss per share, basic and diluted | $(0.08) | $(0.25) | $(0.26) | $(0.52) |
For the six months ended June 30, cash used in operating activities was $34.5 million, compared with $74.6 million in H1 2022. Investing activities provided $19.3 million, largely reflecting investment maturities net of purchases; financing activities provided $2.8 million. Cash, cash equivalents and restricted cash declined to $81.7 million from $94.2 million at December 31, 2022. Short-term investments were $269.0 million, bringing cash and investments to $350.7 million; working capital was $354.2 million.
At June 30, total liabilities were $156.6 million, including $93.4 million of finance lease liability for the Lonza monoplant and $7.8 million of operating lease liabilities. The monoplant lease began in Q2; Aurinia recorded a $117.6 million right-of-use asset and a corresponding lease obligation at inception. The filing does not report conventional borrowings. Interest income was $4.1 million in Q2 and $7.9 million in H1, up from $0.5 million and $0.7 million, respectively, mainly due to higher investment yields. Other income included valuation and foreign-exchange effects.
Changes and management commentary
- Revenue increased 47% in Q2 and 52% in H1 year over year, primarily from greater LUPKYNIS market penetration. Aurinia reported approximately 1,911 patients on therapy at June 30, 2023, versus approximately 1,274 a year earlier.
- Operating and net losses narrowed substantially year over year. H1 SG&A was broadly flat at $97.2 million; H1 R&D increased to $25.8 million from $24.1 million, reflecting clinical supply, personnel and share-based compensation, partly offset by lower CRO costs.
- Management stated that available cash and investments should fund current plans for at least the next few years, including commercialization, post-approval commitments and pipeline development. This is management’s estimate, not a guarantee.
- On June 29, 2023, the Board initiated an exploration of strategic alternatives. The filing cautions that no particular transaction or other strategic outcome is assured or necessarily timely.
- Aurinia projected IND submissions (or equivalent) for AUR200 in 2023 and AUR300 in 2024. No specific revenue, earnings or cash-flow guidance was provided.
Risks, contingencies and unusual items
- Customer concentration is high: two U.S. customers accounted for about 98% of total revenue and 98% of net trade receivables. Aurinia also extended nominal customer discounts through the end of 2023; discounts and inventory purchasing patterns may contribute to revenue fluctuations.
- Patient-start forms and patients on therapy do not directly predict revenue. Conversion, treatment duration, access and customer ordering can vary; some patients may receive free drug or discontinue treatment.
- The company faces a shareholder class-action lawsuit alleging misleading statements concerning financial guidance and commercial prospects. The amended complaint was filed May 22, 2023; Aurinia said it intends to defend the action. Management said resolution of contingencies is not expected to materially affect its financial position, but litigation outcomes remain uncertain.
- The Swiss-franc-denominated monoplant finance lease creates currency exposure: Aurinia estimated a 10% Swiss franc movement could change the liability’s valuation by approximately $9.3 million. It also disclosed interest-rate, inflation, supply-chain, geopolitical and credit risks.
- Approximately $2.3 million of finished-goods inventory reserves related primarily to FDA process-validation batches. H1 share-based compensation expense was $21.7 million; $48.4 million of unrecognized compensation expense remained at June 30.
Important facts for investors to verify
- Whether LUPKYNIS revenue growth, patient persistence and customer orders continue to support commercial expansion—and how discounts, inventory levels and patient access affect net sales.
- Progress and timing of the AUR200 and AUR300 IND submissions, LUPKYNIS post-approval commitments, and regulatory approvals in Otsuka territories.
- Updates on the strategic-alternatives review, including whether it produces a transaction or changes operating plans.
- Cash burn, investment balances and runway assumptions, alongside the monoplant’s lease payments, manufacturing performance and foreign-exchange exposure.
- Developments in the shareholder litigation and any changes to customer concentration, receivable collectability or inventory reserves.